Helus Pharma's HLP003 shows Phase 3 depression benefit, with safety questions
Helus Pharma said Monday that its psychedelic drug candidate HLP003 significantly reduced depression scores in a Phase 3 trial, but the study also recorded a number...
AI and the frontier tech around it, explained every morning
Stories about psychedelics · 1 stories
Helus Pharma said Monday that its psychedelic drug candidate HLP003 significantly reduced depression scores in a Phase 3 trial, but the study also recorded a number...